Replimune Group Inc · Q2 2022 earnings

Briefing

Replimune reported financial results for the fiscal second quarter and provided a business update.

Replimune reported its financial results for the second fiscal quarter ended September 30, 2021. The company believes that existing cash and cash equivalents will fund operating expenses and capital expenditure requirements into the second half of 2024.

• Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022.
• Interim data in the IGNYTE anti-PD1 failed registration directed melanoma cohort continues to be expected in late 2022
• Updated monotherapy and combination data with Opdivo (nivolumab) to be presented at SITC this month
• Phase 1 protocol amendment expansion to add additional patients with liver metastases filed

Headline financials

Revenue & EPS history

Replimune believes that existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024, excluding any confirmatory trial required by the FDA or other regulatory body.